Expansion of a subset of CD14(high)CD16(neg)CCR2(low/neg) monocytes functionally similar to myeloid-derived suppressor cells during SIV and HIV infection by Gama, Lucio et al.
  Universidade de São Paulo
 
2012
 
Expansion of a subset of
CD14(high)CD16(neg)CCR2(low/neg)
monocytes functionally similar to myeloid-
derived suppressor cells during SIV and HIV
infection
 
 
JOURNAL OF LEUKOCYTE BIOLOGY, BETHESDA, v. 91, n. 5, supl. 1, Part 3, pp. 803-816, MAY,
2012
http://www.producao.usp.br/handle/BDPI/36335
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Sem comunidade WoS
Expansion of a subset of
CD14highCD16negCCR2low/neg monocytes
functionally similar to myeloid-derived
suppressor cells during SIV and HIV infection
Lucio Gama,*,†,1 Erin N. Shirk,* Julia N. Russell,* Karina I. Carvalho,† Ming Li,*
Suzanne E. Queen,* Jorge Kalil,† M. Christine Zink,* Janice E. Clements,*
and Esper G. Kallas†
*Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland,
USA; and †Division of Clinical Immunology and Allergy, University of Sa˜o Paulo School of Medicine, Sa˜o Paulo, Brazil
RECEIVED NOVEMBER 25, 2011; REVISED FEBRUARY 3, 2012; ACCEPTED FEBRUARY 5, 2012. DOI: 10.1189/jlb.1111579
ABSTRACT
Monocytes have been categorized in three main sub-
populations based on CD14 and CD16 surface expres-
sion. Classical monocytes express the CD14CD16
CCR2 phenotype and migrate to inflammatory sites by
quickly responding to CCL2 signaling. Here, we identi-
fied and characterized the expansion of a novel mono-
cyte subset during HIV and SIV infection, which were
undistinguishable from classical monocytes, based on
CD14 and CD16 expression, but expressed significantly
lower surface CCR2. Transcriptome analysis of sorted
cells demonstrated that the CCR2low/neg cells are a dis-
tinct subpopulation and express lower levels of inflam-
matory cytokines and activation markers than their
CCR2high counterparts. They exhibited impaired phago-
cytosis and greatly diminished chemotaxis in response
to CCL2 and CCL7. In addition, these monocytes are
refractory to SIV infection and suppress CD8 T cell
proliferation in vitro. These cells express higher levels
of STAT3 and NOS2, suggesting a phenotype similar to
monocytic myeloid-derived cells, which suppress ex-
pansion of CD8 T cells in vivo. They may reflect an an-
tiproliferative response against the extreme immune
activation observed during HIV and SIV infections. In
addition, they may suppress antiviral responses and
thus, have a role in AIDS pathogenesis. Antiretroviral
therapy in infected macaque and human subjects
caused this population to decline, suggesting that this
atypical phenotype is linked to viral replication. J. Leu-
koc. Biol. 91: 803–816; 2012.
Introduction
Monocytes have often been described as transitional cells of
myeloid origin, whose main function is to replenish the phago-
cyte population in tissues through differentiation into macro-
phages and other specialized cells, such as microglia,
osteoclasts, and DCs [1]. However, during their short life in
the blood, monocytes are far from bystanders; they are con-
stantly patrolling the vasculature, detecting pathogens and un-
wanted cells, and clearing them from the circulation [2]. They
also quickly respond to chemokine signals by trafficking to tis-
sues upon stimulation, as well as mediating important func-
tions in immune responses by producing copious amounts of
cytokines [3, 4].
Circulating monocytes derive from hematopoietic stem cells
in the bone marrow and can be easily distinguished from
other leukocytes when analyzed by flow cytometry, presenting
a CD3negCD20negCD11bhighCD14high/low phenotype [5–7].
They can also be separated into different subpopulations with
distinct surface markers and biological functions [1]. Based on
expression levels of CD14 (LPS receptor) and CD16 (FcRIII),
three well-defined monocyte subpopulations have been identi-
fied in humans and nonhuman primates: CD14CD16, re-
ferred to as classical or inflammatory; CD14lowCD16high (or
CD14dimCD16), referred to as nonclassical, resident, or pro-
inflammatory; and a transitional subpopulation of
CD14highCD16, referred to as intermediate. Similar func-
tional subpopulations are found in mice and rats, although
other surface markers (Ly6C, 7/4) are used for such classifica-
tion [5, 8, 9].
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Classical monocytes express CCR2 and migrate into the cir-
culation and toward inflammatory sites, mainly through CCL2
(or MCP-1)-dependent signaling. Upon reaching the target
tissues, they differentiate into macrophages or in some sites,
DCs [10–12]. Conversely, nonclassical monocytes appear to
represent a more advanced stage of differentiation, closer to
resident macrophages, and they are the main subpopulation
supplying resident macrophages and DCs to healthy tissues
[13]. They migrate into tissues in response to MIP-1 (or
CCL3), CCL5 (or RANTES), and CX3CL1 (or fractalkine in
humans) but not CCL2, as they lack CCR2 on their surface [1,
5]. In humans, this CD14dimCD16 subset patrols the endo-
thelium of blood vessels and responds to viruses via TLR7 and
-8, in contrast to classical and intermediate monocytes, which
respond to bacteria-associated signals [2].
Several novel blood monocyte phenotypes have been de-
scribed recently, indicating that their heterogeneity is not re-
stricted to the three classical subtypes. Monocytes expressing
the angiopoietin receptor Tie-2 exhibit marked proangiogenic
activity and account for 35–75% of the nonclassical subset in
the blood of human cancer patients [14]. CD16highCCR2
monocytes, producing high levels of HO-1, may play an anti-
inflammatory role during Kawazaki disease and influenza virus
infection [15, 16], and a subset of CD14lowCD16 cells ex-
pressing the FcRI CD64, in conjunction with high levels of
HLA-DR, CD11c, and CD86, possibly represents an intermedi-
ate phenotype between monocytes and DCs [17]. CD14HLA-
DRlow/neg immunosuppressive monocytes have been identified
in many cancer patients [18, 19], although cells presenting a
similar phenotype have been reported in other neoplasias and
were classified as monocytic MDSCs [20, 21].
In HIV and SIV infection, the expansion of specific monocyte
subsets has been associated with the development of HAND, and
a high rate of monocyte turnover correlates with AIDS progres-
sion in SIV-infected macaques [7, 22, 23]. In this study, the analy-
sis of monocyte subpopulations during acute SIV infection using
our consistent, accelerated animal model for HAND and HAART
led to the discovery of a CD14CD16 monocyte subset that
lacks surface CCR2, rendering them unresponsive to CCL2.
These cells express a unique transcriptome, impaired phagocyto-
sis and chemotaxis, and are refractory to viral infection. They also
express higher levels of STAT3 and NOS2 and are able to inter-
fere with the proliferation of CD8 T cells in vitro, which leads
us to suggest that this novel subset could be classified as MDSC,
with an antiproliferative role during SIV infection. In parallel, we
demonstrate that HIV-1-infected human subjects also have this
monocyte subset and that efficacious antiretroviral treatment, in
macaques as in humans, is able to revert the frequency of this
population back to preinfection levels. We demonstrate that HIV
and SIV infection lead to changes in monocyte phenotype and
that these changes impact early immune responses, which may
affect virus pathogenesis.
MATERIALS AND METHODS
Animals
Forty-five juvenile pigtailed macaques (Macaca nemestrina) were inoculated
i.v. with SIV/DeltaB670 and SIV/17E-Fr, as described previously [24]. Be-
ginning on Day 12 p.i., six animals were treated with a combination of four
antiretroviral drugs (PMPA, saquinavir, atazanavir, and the integrase inhibi-
tor L-870812) and were euthanized after 160–186 days p.i., as described
elsewhere [25]. Groups of SIV-infected, untreated animal (six each) were
euthanized after 7, 14, and 21 days p.i. All other animals were euthanized
between 50 and 90 days p.i. Two macaques were mock-inoculated and used
as procedure controls. Before euthanasia, animals were perfused with ster-
ile PBS, and tissues were harvested for fixing and freezing. All procedures
were done in accordance with federal and institutional policies.
Patients
Samples were selected from a cohort designed to recruit recently HIV-1-
infected people in 2002 in Sa˜o Paulo, Brazil [26, 27]. All procedures ad-
opted in this study were performed according to the terms agreed by the
Institutional Review Board from the Hospital das Clı´nicas, University of Sa˜o
Paulo (CAPPesq, Research Projects Ethics Committee, Sa˜o Paulo, Brazil).
This study was approved by CAPPesq under Protocol 0148/11, and written,
informed consents were obtained from all volunteers. Recent HIV infection
was determined by the serological test algorithm for recent HIV serocon-
version. Subjects were included in the study when they had a negative, de-
sensitized ELISA HIV-1 test. Antiretroviral treatment was initiated when
CD4 T cell count was 300 cells/l or upon identification of any AIDS-
defining condition. We randomly selected 12 subjects to evaluate the early
infection monocyte subpopulations at baseline, 3 months, and post-6
months. Another group of six subjects was evaluated before and after initia-
tion of antiretroviral therapy.
Samples
Macaque blood samples were collected at multiple time-points before and
after inoculation. Whole blood was used for cytometry analysis. For some
experiments, PBMCs, previously collected at different time-points, were rap-
idly thawed in 25% FBS RPMI and kept on ice to maintain monocyte viabil-
ity. After a cold wash with 10% FBS RPMI, viable cells were enriched using
the Annexin V MicroBead kit (Miltenyi Biotec, Auburn, CA, USA) and ali-
quoted for FACS analysis and functional assays, as described below. For hu-
man samples, PBMCs were thawed, checked for viability, and used for flow
cytometry assays, also described below. For in vitro evaluation of CCR2 ex-
pression, PBMCs were transferred to low cell-binding HydroCell plates
(Nunc, Rochester, NY, USA), incubated overnight in 10% FBS RPMI con-
taining 100 ng/ml CCL2 (ProSpec, Charlotte, NC, USA) or 1 ng/ml LPS
(Sigma-Aldrich, St. Louis, MO, USA), and analyzed by flow cytometry.
Flow cytometry
Macaque blood samples were stained with FITC-conjugated anti-CD14, PE-
conjugated anti-CCR2, and PE-Cy5-conjugated anti-CD16 antibodies (see
Supplemental Table 1) for 20 min at room temperature. Cells were fixed
for 10 min with Lyse/Fix buffer (Becton Dickinson, Franklin Lakes, NJ,
USA), and for intracellular staining, cells were permeabilized using Cyto-
fix/Cytoperm (Becton Dickinson). Analyses were performed on a
FACSCalibur flow cytometer using CellQuest software. PBMCs from frozen
samples were stained with different antibody combinations for 30 min on
ice. Panels with information for all antibodies can be found in Supplemen-
tal Table 1. After fixation, samples were analyzed on a BD LSRFortessa cell
analyzer using DIVA software. Human PBMCs and cells used in other ex-
periments were processed similarly and evaluated on a BD FACSCanto or
LSRFortessa flow cytometer using DIVA software. All data acquired were
analyzed using FlowJo software. Positivity for each antibody was determined
by FMO.
Quantification of SIV virions
Viral RNA was isolated from plasma using the QIAamp Viral RNA Mini Kit
(Qiagen, Valencia, CA, USA) and analyzed by qPCR, as described previ-
ously [28].
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Quantification of CCL2
Levels of plasma CCL2 were measured using the Quantikine Human for
MCP-1 ELISA Kit (R&D Systems, Minneapolis, MN, USA), following the
manufacturer’s protocol.
Sorting
Macaque PBMCs were thawed as described above and stained with anti-
CD3 and anti-CD20 (FITC), anti-CD14 (PerCP-Cy5.5), anti-CD16 (PE), and
anti-CCR2 (allophycocyanin) antibodies (Supplemental Table 1). After 30
min on ice, cells were fixed with 4% formaldehyde and sorted on a BDAria
Special Order cytometer. Purity of sorted populations varied from
95% to 98%.
Nucleic acid extraction
Genomic DNA and total RNA were isolated from sorted cells using the All-
prep DNA RNA formalin-fixed, paraffin-embedded kit (Qiagen) with modi-
fications. Briefly, cells were pelleted and resuspended in PKD buffer with
10 l proteinase K. Samples were incubated for 15 min at 55°C and then
for 5 min on ice. Lysates were centrifuged at 10,000 g for 15 min. Pellets
were resuspended in ATL buffer, and DNA was extracted, according to the
manufacturer’s instructions. Supernatants containing the RNA were incu-
bated for 15 min at 80°C and then mixed with two volumes of 100% etha-
nol and 1 g carrier RNA (Qiagen). After 30 min at 20°C, RNA was pel-
leted by centrifugation and resuspended in 6 l RNase-free water.
mRNA quantification
CodeSets for 90 macaque genes were designed according to NanoString
specifications, based on rhesus macaque (Macaca mulata)-published se-
quences. RNA samples were hybridized for 16 h with the CodeSet, and
genes were quantitated using the nCounter Digital Analyzer [29]. Data
were normalized initially by the average of the values from spiked, positive
standards and then by the geometric mean of four housekeeping genes.
Raw data with values lower than the background controls were considered
negative. Results were deposited at the Gene Expression Omnibus data-
base, under Accession Number GSE27559 (http://www.ncbi.nlm.nih.gov).
Viral DNA quantification
DNA samples were analyzed for SIV gag by qPCR, as described previously
[30]. SIV circular 2-LTR was quantitated in the same reaction tubes using
the following set of primers and probe: 2LTR forward-GAAGACCCTG-
GTCTGTTAGGACC; 2LTR reverse-CTTGCACTGTAATAAATCCCTTCCA;
2LTR-HEX-TTTGGGAAACCGAAGCAGGAAAATCC. Copy numbers were
determined by extrapolation from standard curves generated by serial dilu-
tion of plasmids containing the specific DNA sequences for each amplicon.
Results were normalized to copy numbers of a single-copy cellular gene
(IFN-).
Phagocytosis assay
Macaque PBMCs were thawed as described above. Cells (2105) were re-
suspended in 10% FBS RPMI and placed in HydroCell low-adherence
plates (Nunc), mixed with 20 l Escherichia coli particles, covered with
pHrodo (Life Technologies, Carlsbad, CA, USA), a nonfluorescent dye that
gains fluorescence in acidic milieu, such as lysosomes. After 30 min at
37°C, cells were placed on ice and stained with conjugated antibodies for
FACS analysis. Besides plating cells without pHrodo for viability control,
cells were also plated with pHrodo but kept on ice to prevent phagocytosis
and were used as negative control.
Chemotaxis assay
BD BioCoat Matrigel Invasion Chambers were used for chemotaxis experi-
ments, following the manufacturer’s instructions. This transwell system con-
tains a top insert containing a 10-M pore membrane covered with a gelati-
nous matrix that prevents transmigration of noninvasive cells. Top inserts
holding 500 l, containing 105 thawed PBMCs, were transferred to a Hy-
droCell low-adherence, 24-well plate with 100 ng/ml CCL2, CCL3, or CCL7
(ProSpec) in 500 l 10% FBS RPMI. Wells containing only media were
used as background control for each sample. After 24 h of incubation at
37°C, cells that migrated to the bottom wells were split in two groups: 30%
were counted in a hemocytometer, and 70% were stained for FACS analy-
sis.
Lymphoproliferation assay
Lymphocytes and other nonmonocytic cells were isolated from fresh
PBMCs from two uninfected macaques using anti-CD14 magnetic beads
and labeled with a tracer dye (Vybrant DiI, Life Technologies) for 10 min.
After two washes, cells were cultivated in RPMI with 10% macaque serum,
25 g/ml PHA (Sigma-Aldrich), 2 U/ml IL-2 (ProSpec), and 5 M ZDV.
Concomitantly, CD14highCD16CCR2low/neg monocytes were isolated from
thawed PBMCs, collected from three SIV-infected animals, euthanized at 14
days p.i., using the Monocyte Isolation Kit II (Miltenyi Biotec) in combina-
tion with biotinylated anti-CCR2 (R&D Systems). Once purified,
CD14highCD16CCR2low/neg monocytes were added to labeled cells (10,000
monocytes for 100,000 nonmonocytic cells) in proliferation media. Cell
sorting by magnetic beads resulted in a 95% pure population of
CCR2low/neg classical monocytes but only a 30–40% pure population of
CCR2high cells. Therefore, as control, we used monocytes
CD14CD16CCR2 similarly isolated from thawed PBMCs from three un-
infected macaques using the same protocol minus the anti-CCR2 antibody.
After 72 h, the supernatant was stored for IFN- quantification, and cells
were collected and stained for FACS. Proliferation levels were analyzed by
FlowJo.
IFN- quantification
Supernatants collected from the lymphoproliferation assay were incubated
with anti-IFN- cytometric beads (Becton Dickinson), according to the
company’s protocol. Data were acquired on a BD LSRFortessa and analyzed
by FCAP array software (Becton Dickinson).
Statistical analysis
Differences in absolute numbers of cells and in CCR2hi/CCR2low/neg classi-
cal monocyte ratios at different time-points were analyzed by Wilcoxon
paired rank test. Bivariate analyses were done using Spearman’s rank corre-
lation test. All other results were analyzed using Mann-Whitney t test. Outli-
ers were defined by applying the Grubbs test [31]. Calculations were per-
formed using Prism software (GraphPad Software, La Jolla, CA, USA), and
statistical significance was set as P  0.05.
RESULTS
Circulating monocyte subpopulations change during
acute SIV infection
In the consistent, accelerated SIV model for HIV/AIDS and
CNS disease, pigtailed macaques are inoculated with the im-
munosuppressive swarm SIV/DeltaB670 and the neurotropic
molecular clone SIV/17E-Fr, leading to the onset of AIDS and
encephalitis within 3 months [30]. Viral mRNA in the brain
can be detected as early as 4 days p.i., and macrophages, de-
rived from monocytes that recently migrated from the periph-
eral blood, represent the main source of viral replication [32].
To investigate the contribution of circulating monocytes in the
early events observed in the brain, blood samples from 18 SIV-
infected macaques were collected before virus inoculation and
at 7, 10, 14, 21, and 28 days p.i. and analyzed by flow cytom-
etry. Monocytes were initially distinguished from other leuko-
Gama et al. Suppressive monocytes in HIV/SIV infection
www.jleukbio.org Volume 91, May 2012 Journal of Leukocyte Biology 805
cytes by FSC and SSC and then assessed according to their
levels of CD14 and CD16 expression (Fig. 1A). As proposed
by the Nomenclature Committee of the International Union
of Immunological Societies, classical monocytes were de-
fined as CD14CD16, intermediate monocytes as CD14high
CD16, and nonclassical monocytes as CD14dimCD16 [33].
Cells expressing low levels of CD14 and no CD16 have been
identified previously as a heterogeneous population of non-
monocytic leukocytes and were not considered in our analy-
ses [8].
A significant change in the total number of circulating
monocytes was observed in the first 28 days p.i. and was char-
acterized by three distinct phases: an initial period of decline,
followed by expansion, and a return to preinoculation levels
(Fig. 1B). Although all individual subsets presented similar
trends (Figs. 1C), their contribution to the overall population
in each of the three phases were noticeably different. At 7 days
p.i., the absolute number of classical and intermediate mono-
cytes was reduced significantly (P0.05 for both), indicating
that they were the main subsets driving the initial depletion
observed in the total population. Both subsets were CD14high,
whereas no significant change was observed in the
CD14dimCD16 nonclassical subgroup (P0.31). After this
transient decrease, all subpopulations expanded significantly
(Fig. 1B), leading to a pronounced, albeit temporary, monocy-
tosis at 14 days p.i. In the third phase, the total monocyte de-
cline appeared to be the result of classical monocyte fluctua-
tions (P0.03), as no significant variation was detected in sub-
populations expressing CD16 (P0.12 for intermediate, and
P0.65 for nonclassical monocytes; Fig. 1C). These results sug-
gest that CD14CD16 cells were the main driver of monocyte
changes during acute infection.
CCR2 is down-regulated in classical monocytes during
SIV acute infection
It is well established that CD14CD16 monocytes express
high levels of CCR2 on their surface [3]. As we were charac-
terizing changes in the monocyte population during acute
infection, we observed a dramatic down-regulation of sur-
face CCR2 expression, specifically in the CD14CD16 sub-
set as early as 7 days p.i. (Fig. 2A and B). In contrast, inter-
mediate CD14highCD16 monocytes, which constitute a het-
erogeneous population regarding the expression of several
surface proteins, manifested no significant change in CCR2
expression when compared with steady-state levels.
CD14highCD16CCR2low/neg monocytes expanded consid-
erably at 14 days p.i. (Fig. 2C) but were reduced at Day
21 p.i., remaining higher than preinfected levels through-
out infection. CCR2high classical monocytes also expanded
from 7 to 14 days p.i. but slowly declined to preinfected lev-
els after 21 days p.i., with a distinct longitudinal profile
when compared with the CCR2low/neg subset (Fig. 2B
and C).
During acute SIV infection, the ration between CCR2high
and CCR2low/neg subsets changed dramatically, and by Day
7 p.i. 50% of circulating classical monocytes were
CCR2low/neg. Even with the increase of CD14highCD16
CCR2high cells after Day 10 p.i., the ratios between CCR2high
and CCR2low/neg classical monocytes were not restored to
preinfected levels and remained significantly lower through-
out infection (Fig. 2D).
To evaluate the role of CCL2 in the down-regulation of sur-
face CCR2 expression, PBMCs from uninfected macaques were
cultivated overnight in RPMI media with CCL2 (100 ng/ml).
As positive control, cells were exposed to bacterial endotoxin
Figure 1. Changes in monocyte subpopu-
lations during SIV acute infection. (A)
Gating strategy used to discriminate
monocyte subsets [classical monocytes
(red), intermediate monocytes (green),
and nonclassical monocytes (blue)]. (B)
Absolute number of total circulating
monocytes. Solid line represents the me-
dian of 18 SIV-infected macaques. (C)
Absolute number of each monocyte sub-
set. Solid lines represent the median of
all animals. (B and C) Asterisks denote
Wilcoxon paired rank test; P values be-
tween absolute number of cells at the fol-
lowing time-points: *uninfected versus 7
days p.i.; **7 days versus 14 days p.i.; and
***14 days versus 21 days p.i.
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(LPS), a strong CCR2 expression modulator [34]. Although
CCL2 has been reported to quickly down-regulate CCR2 sur-
face expression in RBL-2H3-transfected cells [35], no signifi-
cant change was observed in primary monocytes under CCL2
treatment overnight (Fig. 2E). Similar results were observed in
human embryonic kidney-293T cells transfected with a rhesus
CCR2 construct [36] treated under the same conditions (data
not shown), indicating that long-term treatment with CCL2
does not alter CCR2 surface expression significantly and that
the lower detection of CCR2 expression that we observed in
vivo was not caused by interactions between agonist and re-
ceptor, which could block the access of cytometry antibod-
ies to their specific epitopes. In vivo analysis corroborated
these finding, showing a small correlation (r0.18; P0.05)
between levels of plasma CCL2 measured by ELISA and the
absolute number of CD14highCD16CCR2low/neg cells (Sup-
plemental Fig. 1A). Other biological parameters frequently
measured during HIV/SIV infection, such as viral load and
levels of CD4 and CD8 T cells, did not correlate with the
frequency of this new CCR2low/neg subset (Supplemental
Fig. 1B–D).
The loss of surface CCR2 could impact cell trafficking to
tissues and efficient responses during infection and inflamma-
tion. Therefore, we postulated that in addition to the dramatic
down-regulation of CCR2 expression, other changes might be
occurring in this subset and that CD14highCD16CCR2low/neg
Figure 2. CCR2 is down-regulated in
classical monocytes during acute infec-
tion. (A) Histograms demonstrate the
specific down-regulation of CCR2 ex-
pression on CD14CD16 monocytes at
7 days p.i. Unstained control (defined
by FMO) is represented in light gray.
Uninfected samples are represented by
dark gray lines and 7 days p.i., by col-
ored lines. Each row represents one
macaque. Representative of 18 animals.
(B) CCR2 surface expression on classi-
cal monocytes during acute SIV infec-
tion. Brackets represent the percentage of CCR2low/neg. Unstained control is represented in light gray. Representative of 18 animals. (C) Absolute
number of CCR2low/neg and CCR2high classical monocytes in 18 SIV-infected macaques until 70 days p.i. Solid lines represent median. (D) Ratio
between CCR2high and CCR2low/neg classical monocytes for each time-point. Median differences between uninfected and each time-point were an-
alyzed by Wilcoxon paired rank test. *P  0.01; **P  0.05. (E) Surface CCR2 expression on uninfected classical monocytes exposed overnight to
CCL2 (100 ng/ml) and LPS (1 ng/ml). Unstained control is represented in light gray. Untreated controls are represented by blue lines and
treated cells by red lines. Representative of three experiments.
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monocytes represent a distinct, functional phenotype when
compared with their CCR2high counterparts.
CD14highCD16CCR2low/neg monocytes display a
transcriptome distinct from classical monocytes
To investigate the mRNA expression profile of CCR2high
and CCR2low/neg classical monocytes, cells from six SIV-in-
fected macaques were FACS-sorted according to their sur-
face marker phenotype (Supplemental Fig. 2). Longitudi-
nally acquired blood samples were limited in volume; there-
fore, viably frozen PBMCs collected during necropsy from
macaques euthanized at 14 days p.i. were used. Each sub-
set’s transcriptome was analyzed by NanoString, using a
panel of 90 probes specifically designed for the detection
and quantitation of macaque genes associated with inflam-
matory and immuneregulatory processes. The specificity of
the probe set was confirmed using spleen and brain tissue
from uninfected and SIV-infected pigtailed macaques (data
not shown).
CD14highCD16CCR2low/neg presented a unique pheno-
type, based on 78 genes that were expressed in at least one
subset. Levels of expression of 41 genes were distinct be-
tween CCR2high and CCR2low/neg classical monocytes with P
values  0.05 (Fig. 3A). Among the 41 transcripts with dif-
ferential expression between the two subsets, 31 (34.4% of
all genes in the array) were expressed at lower levels in
CD14highCD16CCR2low/neg monocytes, including the typi-
cal inflammatory cytokines TNF-, IL-6, IL-7, IL-1, IL-27,
CCL3, CCL4, CCL19, CXCL3, CXCL9, CXCL10, XCL1,
IFN-, and IFN-2. Accordingly, they also expressed lower
Figure 3. Relative mRNA expres-
sion between sorted CD14CD16
CCR2high and CD14CD16
CCR2low/neg monocytes from six
SIV-infected macaques at 14 days
p.i. (A) Classical monocytes from
PBMCs collected at 14 day p.i.
were FACS-sorted according to
their CCR2 surface expression.
Total RNA from both subsets was
isolated and analyzed by Nano-
String technology. Graphics illus-
trate relative fold change in gene
expression, comparing CCR2high
with CCR2low/neg classical mono-
cytes. Genes are separated in fami-
lies and listed according to their P
values. Gray boxes denote statisti-
cal significance between the two
subsets (Wilcoxon paired rank test
P0.05). TNFRsf8, TNFR super-
family 8; TNFLigsf13, TNF ligand
superfamily 13; SPP1, secreted
phosphoprotein 1; MDA5, mela-
noma differentiation-associated
gene 5; TYK2, tyrosine kinase 2;
SOCS3, suppressor of cytokine sig-
naling 3. (B) Protein expression of
various genes in CCR2high (black
lines) and CCR2low/neg (dark gray
lines) classical monocytes evalu-
ated by flow cytometry. Unstained
controls are illustrated in light
gray-filled histograms. Numbers
inside the graphics represent the
mean fluorescence intensity of
each subset, shaded as described
above. Representative of three ani-
mals.
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levels of IRF1, IRF7, STAT5a, and IFN-stimulated genes, in-
cluding OAS2 and ZBP1.
CD14highCD16CCR2low/neg monocytes presented higher
levels of TLR3 and TLR5 and lower levels of TLR6, TLR4, and
TLR7 when compared with their CCR2high counterpart, as well
as undetectable levels of TLR9 (Supplemental Fig. 3A). In ad-
dition to TLR3 and TLR5, CD14highCD16CCR2low/neg mono-
cytes presented higher levels of transcripts for two IFN-related
receptors (IL-28R, IFNR1) and less-characterized cytokines
(CCL20, CCL13, CCL8). They also presented significantly
higher levels of STAT3 and NOS2, suggesting that these cells
have an immunosuppressive phenotype, similar to
MDSCs [21].
Thirty-six of the analyzed mRNAs demonstrated no signifi-
cant change between the two populations, although in some
cases, P values were 0.05 as a result of a single outlier, de-
fined by Grubbs test [31]. Removal of the outlier made CCR5
and IL-12A significantly higher in classical monocytes (from
P0.11 and P0.26, respectively, to P0.05). We observed no
relative change in the expression of IL-4, IL-10, IL-18bp,
CCL2, CCL5, CCL24, CXCL2, or CXCL11. Some cytokines
were undetectable for both subsets in all samples (IL-9, IL-13,
IL-17, IL-25, IL-28A/B, IL-29, CCL1, and CCL7).
To corroborate our transcriptome findings, we evaluated the
expression of several proteins in both subpopulations by flow
cytometry, including some genes that were not part of our
NanoString array, such as AGTR2, CD11b, CD33, CD56, CCR6,
and HLA-DR. The combination of data from RNA and protein
analyses confirmed the monocytic phenotype of the
CCR2low/neg cells. They expressed the myeloid markers CD33
and CD11b and slightly higher levels of CD14 and CD16. Both
populations expressed similar levels of CD68 and also CD56, a
surface marker typically associated with NK cells in humans
but that identifies monocytes in macaques [37]. HLA-DR was
also down-regulated in these monocytes, similarly to what has
been reported in monocytic MDSCs in cancer [18, 19]. Lower
levels of CCR2 mRNA in CD14highCD16CCR2low/neg mono-
cytes were observed in three of the six animals (Supplemental
Fig. 3B), indicating that other factors, such as protein turn-
over, might be involved in the reduction of membrane expres-
sion. Although lacking CCR2 on their membranes, these cells
still express receptors known to respond to chemokines in
monocytes, such as AGTR2, CCR1, and CX3CR1 [38–40]. We
also observed a slight but not significant increase of NOS2
protein expression in the CCR2low/neg cells.
CD14highCD16CCR2low/neg monocytes also presented a
dramatic reduction in the mRNA and surface protein levels of
CD4, which is known to be expressed in monocytes in certain
circumstances [41]. These results, together with the down-reg-
ulation of surface CCR5, suggest that these cells might be re-
sistant to SIV and HIV infection.
These results strongly support that CD14highCD16
CCR2low/neg cells are a distinct subset within classical mono-
cytes. As several of these variations could interfere with func-
tions normally ascribed to monocytes, we investigated whether
CD14highCD16CCR2low/neg monocytes were able to properly
phagocytize and respond to chemoattractants.
CD14highCD16CCR2low/neg monocytes present
impaired phagocytosis and chemotaxis
To investigate whether CD14highCD16CCR2low/neg cells re-
tained phagocytic abilities when compared with classical mono-
cytes from healthy subjects, viably frozen PBMCs from unin-
fected and SIV-infected macaques euthanized at 7, 14, and 21
days p.i. were exposed to E. coli covered in pHrodo, a dye that
is not fluorescent at neutral pH but fluoresces when located in
acidic milieu, such as phagosomes and lysosomes.
More than 80% of monocytes from uninfected macaques
were positive for pHrodo fluorescence, in contrast to 58% and
51% of monocytes from 7- and 14-day p.i. samples, respectively
(Fig. 4A). Control monocytes presented higher mean fluores-
cence, which indicates a larger intake of particles/cell (Fig.
4B). There was no significant difference between uninfected
and 21-day-p.i. samples, suggesting that monocytes regained
their ability to efficiently phagocytize after acute infection.
The maintenance of PBMCs in culture at 37°C for the dura-
tion of this experiment was enough to increase the surface
expression of CD16 in classical monocytes, even in the absence
of pHrodo, likely as part of their programming to differentiate
into macrophages [42]. Distinctions between classical and in-
termediate monocytes were harder to establish, but it was no-
ticeable that at all time-points, only CCR2high cells among the
two CD14 subtypes were also positive for pHrodo (Fig. 4C).
Expression of CCR2, as expected, was not essential for effi-
cient phagocytosis, as 50% of nonclassical monocytes
CD14dimCD16, which do not express CCR2, were also
pHrodo-positive. These data indicate that monocytes, in gen-
eral, present a transitory phase of impaired phagocytosis after
SIV infection and that the CD14highCD16CCR2low/neg mono-
cytes are affected specifically by this dysfunction in all time-
points examined.
We also analyzed the ability of monocytes, at 14 days p.i., to
respond to CCL2 signaling using a transwell migration assay.
PBMCs from uninfected or infected macaques at 14 days p.i.
were placed on top inserts and transferred to wells containing
medium with 100 ng/ml CCL2, CCL3, or CCL7 [43]. After
24 h, cells were collected from the bottom wells and stained
for FACS analyses.
In samples from uninfected monkeys, PBMCs started trans-
migrating to the lower chambers as early as 4 h after plating.
Although we observed transmigrated cells even in media con-
taining no chemoattractant, only wells with CCL2 and CCL7
contained CD14 monocytes (Fig. 4D). Levels of CD14 and
CCR2 appeared lower than what we normally observed in
fresh PBMCs, suggesting that monocytes down-regulated sur-
face expression during or after transmigration. In the wells
holding 14-day-p.i. PBMCs, as shown in Fig. 4D and E, we ob-
served a significant reduction in transmigrated cells, indepen-
dent of the chemoattractant. We observed almost no
CD14CCR2high leukocytes, paralleling the previous observa-
tion that monocytes, in general, have impaired function dur-
ing acute infection and that CD14highCD16CCR2low/neg cells,
specifically, do not respond to chemokine signaling in this as-
say. Samples from infected animals at 14 days p.i. still con-
tained a large number of CCR2high cells before transmigrating
Gama et al. Suppressive monocytes in HIV/SIV infection
www.jleukbio.org Volume 91, May 2012 Journal of Leukocyte Biology 809
(20–50% of all classical monocytes), suggesting that besides
lower surface-receptor expression, other factors might play a
role in their dysfunctional chemotactic response. Similar re-
sults were observed with monocytes at 7 and 21 days p.i. (data
not shown).
CD14highCD16CCR2low/neg monocytes impair in
vitro proliferation of CD8, but not CD4, T cells,
and harbor fewer copies of SIV DNA genome
A population of CD14HLA-DRlow/neg cells with a suppres-
sive phenotype has been identified in patients with B cell
non-Hodgkin’s lymphoma [18]. To assess a functional role
of CD14highCD16CCR2low/neg monocytes in lymphoprolif-
eration, we exposed proliferating lymphocytes from unin-
fected macaques to classical monocytes isolated from other
uninfected animals or from CCR2low/neg classical monocytes
from SIV-infected macaques at 14 days p.i. (Fig. 5A). To
prevent virus spread from infected monocytes, cells were
cultivated in 5 M ZDV. After 72 h, we observed a signifi-
cant decrease in the proliferation of CD8 T cells exposed
to CD14highCD16CCR2low/neg monocytes (P0.05), al-
though no significant change was observed in CD4 T cells
(Fig. 5B). Levels of IFN- in the coculture supernatants
were also significantly lower in the wells containing
CD14highCD16CCR2low/neg monocytes (Fig. 5C), even with
the removal of the outlier. Bivariate analysis of in vivo data
showed a significant negative correlation between the per-
centage of monocytes expressing the CD14highCD16
CCR2low/neg phenotype and the percentage of CD69 CD8
T cells, but not CD4 T cells (data not shown), in infected
macaques from 7 to 28 days p.i. (r0.38; P0.01), sug-
gesting that the expansion of this unique monocyte subpop-
ulation might interfere with the development of adaptive
immune responses early during infection (Fig. 5D).
Figure 4.
CD14highCD16CCR2low/neg
monocytes present impaired
phagocytosis and che-
motaxis. (A) Percentage of
monocytes positive for
pHrodo fluorescence at dif-
ferent time-points. Bars rep-
resent medians, and P val-
ues were calculated by
Mann-Whitney t test. (B)
Histograms demonstrate the
intensity of pHrodo red flu-
orescence in total mono-
cytes from uninfected (gray
line) and infected macaques
(black line) at different
time-points. Graphics are
representative of four ex-
periments for each of the
time-points. (C) Total
monocytes from a 14-day-
p.i. macaque, depicting the
expression of CD14 versus
CD16 and pHrodo versus
CCR2. Classical and inter-
mediate monocytes are dis-
played in red and nonclassi-
cal in blue, demonstrating
that the vast majority of
CCR2low/neg cells expressing
the phagocytosis red fluo-
rescent marker includes
nonclassical monocytes.
Similar results were ob-
served at 7 and 21 days p.i.
Graphics are representative of four experiments. (D) Graphs depict cells collected from the bottom of a transwell system containing control media
or media with CCL2 or CCL7 and stained for FACS analysis. After gating on viable cells (Live/Dead Near-IR dye) with the approximate size for
monocytes (upper panels), populations were analyzed for CD14 and CCR2 expression (bottom wells; lower panels). Positivity was determined by
FMO. Bottom wells from uninfected samples presented CD14CCR2low monocytes (blue arrows; lower panels) for both experimental conditions,
whereas few cells from 14 days p.i. transmigrated. The figure is representative of four experiments. (E) Graphic shows the percentage of mono-
cytes that transmigrated after being exposed to CCL2-containing media. Total PBMCs were counted using a hemocytometer, and monocytes were
identified by flow cytometry. After 18 h, all media were collected from the bottom wells, and cells were stained for lineage markers (CD3, CD8,
CD20), CD14, CD16, and CCR2. Monocyte numbers were estimated by flow cytometry, after all events were counted for each sample. Bars repre-
sent medians, and P values were calculated by Mann-Whitney t test.
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Monocytes are targets of HIV and SIV infection and may
support active replication in vivo [44]. Some groups have iden-
tified the CD14CD16 subset as more susceptible to HIV
and SIV infection [8, 45]. To investigate which monocyte sub-
sets harbor viral DNA in our model at 14 days p.i., genomic
DNA samples isolated from classical (CD14highCD16
CCR2high), nonclassical (CD14lowCD16), intermediate
(CD14highCD16), and CD14highCD16CCR2low/neg mono-
cytes, sorted by cytometry, were analyzed by qPCR using sets of
primers and probes specific for SIV gag and circular 2-LTR
sequences. Genomic DNA samples from fixed PBMCs were
used as positive control.
There was no significant difference between the number of
SIV gag DNA copies detected in intermediate and classical
monocytes (P0.58), whereas both subsets had higher levels
than nonclassical monocytes (P0.03 for both; Fig. 5E). Levels
of SIV gag DNA in CD14highCD16CCR2low/neg monocytes
were a median of 9.3 lower than CD14highCD16CCR2high
monocytes (P0.03), 2.9 lower than CD14highCD16 mono-
cytes (P0.03), and 1.8 lower than CD14lowCD16 mono-
cytes (P0.09). We observed no difference in levels of gag
DNA between PBMCs and classical or intermediate monocytes
(P0.43 and P0.68, respectively). However, there were twice
as many copies of SIV gag DNA in PBMCs than in total mono-
cytes (17.3 vs. 9.4, respectively), when considering the median
of all values together, corrected by the proportion of each sub-
set (data not shown). No SIV 2-LTR DNA was detected in any
monocyte subpopulation, although they could be quantitated
in PBMCs (median of 2.45 copies/10,000 cells), suggesting
that monocytes were infected but not sustaining detectable
viral replication. These results, together with data indicating
that CD14highCD16CCR2low/neg express less CD4 and CCR5,
suggest that this novel subset may be less susceptible to SIV
infection.
Monocyte subpopulations revert to uninfected levels
in HAART-treated, SIV-infected macaques
Given that the CD14highCD16CCR2low/neg subpopulation rap-
idly expanded in response to SIV infection, we postulated that
a reverse process would follow as animals initiated treatment
with HAART. Six SIV-infected macaques were treated with a
potent four antiretroviral regimen starting at 12 days p.i.,
which falls within the expansion phase that we observed for all
monocyte subsets. Phenotypic analysis of classical monocytes
demonstrated that at 14 days p.i., the CCR2low/neg subset was
reduced significantly when compared with untreated animals
Figure 5. CD14CD16CCR2 monocytes im-
pair the proliferation of CD8 T cells and har-
bor fewer copies of SIV genomic DNA. (A)
Histograms showing the percentage of prolifer-
ated lymphocytes exposed to classical mono-
cytes from uninfected macaques or CD14high
CD16CCR2low/neg monocytes from SIV-in-
fected macaques at Day 14 p.i. for 72 h under
proliferative conditions. Representative of
three lymphocyte donors cocultivated with
monocytes from three uninfected or three in-
fected animals. (B) Lymphocytes CD8, but
not CD4, cocultivated with CD14highCD16
CCR2low/neg monocytes (R2) presented signif-
icantly fewer cells with low expression of the tracer dye than when cocultivated with classical monocytes from uninfected macaques (R2). (C)
Levels of IFN- in the supernatant of lymphocytes cocultivated in the presence of CD14highCD16CCR2low/neg monocytes (R2) are reduced
when compared with classical monocytes (R2). Values represent fold change over levels of IFN- collected from PBMCs cocultivated in prolifera-
tion media but without monocytes. (B and C) Bars represent medians, and P values were calculated by Mann-Whitney t test. (D) Percentage of
monocytes expressing the phenotype CD14highCD16CCR2low/neg was analyzed against the percentage of CD8 T cells positive for CD69. Each
point represents one time-point (7, 10, 14, 21 days p.i.) for each of 14 animals. Correlations were calculated using Spearman’s rank correlation
test. (E) DNA was isolated from sorted monocytes, and SIV gag was quantitated by qPCR and normalized by 10,000 cells (see Materials and Meth-
ods). Bars represent medians, and P values were calculated by Wilcoxon paired rank test. Each point represents an average of two isolations from
each animal [CCR2 classical monocytes (R2CM); CCR2 classical monocytes (R2CM); intermediate monocytes (IM); nonclassical monocytes
(NCM); PBMC].
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(Fig. 6A). Conversely, the CCR2high subgroup continued to
expand after treatment, and by 21 days p.i., the ratio between
classical and CD14highCD16CCR2low/neg monocytes returned
to steady-state levels found in uninfected macaques (Fig. 6B).
These changes correlate more closely to the suppression of
viral replication, as a result of HAART, than to the decaying
levels of circulating virus, as the median (interquartiles) of SIV
RNA copy equivalent/mL plasma, from 3 to 9 days post-treat-
ment (14 and 21 days p.i.), was 0.75 (0.121.8)  106. These
data suggest that the driving force behind the surge of
CD14highCD16CCR2low/neg monocytes is active replication
not the presence of viral particles.
CD14highCD16CCR2low/neg monocytes are also
detected in HIV-infected patients and decrease in
numbers after HAART therapy
To investigate whether humans infected by HIV also presented
an increase of classical monocytes lacking CCR2 surface ex-
pression, we analyzed samples from a cohort of recently HIV-1-
infected patients [27] and compared them with PBMCs col-
lected from negative control individuals (Supplemental Table
2). Uninfected subjects presented a median of 12.9% of
CD14highCD16CCR2low/neg monocytes, with the exception of
two samples, where levels were as high as in some infected pa-
tients (Fig. 7A and B). We attributed these results to a combi-
nation of genetic variability and the lack of information about
the general health status of these individuals. It is possible that
this novel subset is not unique to HIV/SIV infection and may
also increase during other pathological or infectious condi-
tions.
The difference between uninfected and HIV-1-infected indi-
viduals, however, was evident, increasing from 12.9% to 39.1%
in samples acquired when a positive diagnosis was first re-
ported (P0.05). Samples collected from the same patients on
two subsequent occasions demonstrated no significant change
Figure 6. Antiretroviral therapy controls the expansion of CCR2low/neg classical monocytes in SIV-infected macaques. (A) Absolute number of
CCR2low/neg and CCR2high classical monocytes in 18 untreated (red) and six HAART-treated (blue), SIV-infected macaques. Solid lines represent
median. Asterisks denote significant difference (Wilcoxon paired rank test; P0.05) between treated and untreated animals at 14 and 28 days p.i.
(B) Ratio between CCR2high and CCR2low/neg classical monocytes in treated macaques for each time-point. Arrow marks the beginning of treat-
ment at 12 days p.i.
Figure 7. CD14highCD16CCR2low/neg monocytes are ob-
served in humans and expand after HIV infection. (A) Strat-
egy for cytometry analysis of human PBMCs. Monocytes were
gated initially according to size and granularity. Cells express-
ing the viability dye (Live/Dead) and CD3 were excluded.
The last panel shows the percentage of CCR2low/neg classical
monocytes (black line) compared with unstained sample
(gray filled histogram) determined by FMO. (B) Comparison
between the percentage of CCR2low/neg cells among classical
monocytes in uninfected and HIV-infected patients, where
Baseline designates the time when a first HIV diagnostic was
made, and the other two groups represent the period elapsed
after Baseline. Bars represent medians, and P values were cal-
culated by Mann-Whitney t test. (C) Frequency of
CD14highCD16CCR2low/neg monocytes declines after HAART
treatment. Graphic depicts the percentage of CCR2low/neg
cells among classical monocytes in six patients, 1–2 months
before and 1–2 months after starting treatment, and P value
was calculated by Wilcoxon paired rank test.
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in the frequency of this subset (P0.67 for 3 months, and
P0.27 for 6 months after baseline). However, as observed
in our macaque model, patients treated with HAART (Supple-
mental Table 3) also presented a decrease in the percentage
of circulating CCR2low/neg cells among classical monocytes
(Fig. 7C), from a median of 39.9% to levels similar to unin-
fected individuals (13.25%; P0.03), which suggests that simi-
lar mechanisms occur in the modulation of this phenotype
during HIV infection. We were unable to establish an associa-
tion between CD14highCD16CCR2low/neg monocytes and
changes in the absolute number of other circulating leukocyte
populations, including CD4 and CD8 T cells (data not
shown), which is another important similarity between the re-
sults from our SIV model and the human cohort.
DISCUSSION
While characterizing monocyte subpopulations in our acceler-
ated SIV model for AIDS and HIV-associated neurocognitive
disorder, we observed a profound change in the expression of
CCR2 in classical CD14CD16 monocytes, starting early after
inoculation and lasting throughout infection. A similar mono-
cyte subset has been reported in patients with ulcerative colitis
after their blood was depleted of excess granulocytes and
monocytes by extracorporeal adsorption, a treatment that also
leads to the reduction of proinflammatory cytokines and the
increase of anti-inflammatory factors [46]. Therefore, the exis-
tence of circulating CCR2low/neg classical monocytes is not, in
itself, a novel finding, but the sizable expansion and persis-
tence of this subset during HIV and SIV infections had not
been identified previously.
Phenotypic changes in blood monocytes during SIV infec-
tion have been described by several groups in different ma-
caque models, but no study has reported longitudinal altera-
tions in CCR2 surface expression [7, 8, 47–49]. Supporting
some of the findings from other groups, we observed in our
model a reproducible variation in the absolute number of cir-
culating monocytes during acute infection. These were likely
associated with events related to viral replication, including
change in monocyte turnover, death of infected progenitor
cells in the bone marrow, and cell migration toward organs
harboring CCL2-expressing, activated cells [50]. These popula-
tion changes were driven predominantly by CD14CD16
cells, which are the most abundant monocyte subset in the
blood, and normally express high levels of surface CCR2. As
early as 7 days p.i., however, we observed an increase in
CCR2low/neg classical monocytes. Initially, it appeared that the
change was only proportional to CCR2high cells, but further
analysis showed that this novel subgroup was also increasing in
absolute numbers and was maintained in circulation through-
out infection. Besides CD14, these cells also expressed
CX3CR1 and other myeloid markers, such as CD11b and
CD33, confirming their monocytic phenotype.
Although it was impossible to differentiate between these
two subsets based solely on their levels of CD14 and CD16 ex-
pression by flow cytometry, comparative transcriptome analysis
of samples collected at 14 days p.i. showed that they repre-
sented two distinct populations once they were categorized by
their levels of surface CCR2. Based on the mRNA expression
levels of cytokines, however, it was unclear whether they consti-
tuted an anti-inflammatory population, as they expressed lower
levels of the anti-inflammatory cytokine IL-10 and higher levels
of CCL20, CCL13, and CCL8, which are involved in the re-
cruitment of leukocytes [51–53].
Notably, the CCR2low/neg subset expressed higher levels of
STAT3, a transcription factor whose phosphorylation has been
related to cell maturation and anti-inflammatory responses in
macrophages [54]. The latter, together with the observation
that these cells also expressed higher levels of IL-22R2 (a re-
ceptor that heterodimerizes with IL-10R), prompted us to ana-
lyze its ability to perform efficient phagocytosis. It has been
reported that monocyte-derived macrophages from HIV-1-in-
fected patients exhibited defective induction of antiparasite
activity and that monocytes from similar patients were able to
block autophagy in bystander cells through an IL-10/STAT3
signaling [55]. Classical monocytes express high levels of
CD14, TLR4, and TLR2 and are therefore very efficient at re-
sponding to bacterial infection [2]. We observed that although
in lower levels than classical monocytes, these CD14highCD16
CCR2low/neg cells also expressed LPS-sensing receptors, which
should render them responsive to bacterial elements. How-
ever, our results demonstrated that these cells specifically pre-
sented impaired phagocytosis and that all monocytes at 7 and
14 days p.i. responded weakly to E. coli products. They were
also defective in chemotaxis, confirming the above observa-
tions that infection by HIV/SIV can interfere with monocyte
functionality and thwart their ability to react to, capture, and
destroy microbes. As various surface receptors were still detect-
able, including CCR1, CX3CR1, and AGTR2, these cells might
potentially respond to other chemokines instead of CCR2 ago-
nists.
Most importantly, this novel subset was also able to suppress
CD8 T cell proliferation and IFN- release in vitro, and its
expansion in the blood correlated negatively with the percent-
age of in vivo-activated CD8 T cells during acute SIV infec-
tion. Monocytes presenting a similar immunosuppressive
CD14HLA-DRlow/neg phenotype have been previously re-
ported to suppress lymphocyte proliferation in B cell non-
Hodgkin’s lymphoma and prostate cancer [18, 19] and have
been classified by some groups as monocytic MDSCs [56]. Be-
sides showing lower levels of surface HLA-DR, CD14highCD16
CCR2low/neg monocytes share two other distinctive features
with MDSCs. First, they express higher levels of STAT3, the
main transcription factor that regulates MDSC expansion [57].
Second, they also present higher expression of cytokine iNOS
(or NOS2), which has been historically associated with the
suppressive activity of MDSCs, specifically the monocytic subset
[58]. Despite these similarities, future studies are necessary for
a confirmatory classification of these CD14highCD16
CCR2low/neg cells, as no definite parameters have been deter-
mined to distinguish conclusively monocytic MDSCs from
some monocyte subsets [59].
Besides, the transcriptome results and the gradual loss of
surface CCR2 and HLA-DR within the classical monocyte pop-
ulation lead us to postulate that contrary to what is proposed
for MDSCs, this novel subset described here may not originate
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directly from monoblasts but from CD14CCR2high monocytes
already egressed from the bone marrow, a process highly de-
pendent on the CCL2/CCR2 pathway [60]. It is conceivable
that the differentiation itself happens while classical monocytes
shuttle back to the bone marrow, as described previously for
nonclassical monocytes in mouse [61], or while they traffic
through secondary lymphoid organs. Independent of their ori-
gin and nomenclature, the expansion of these suppressor cells
appears to be important for the regulation of the immune sys-
tem during a period of damaging hyperactivation. However,
they may also interfere with antiviral processes by inhibiting
CD8 T cell activation in vivo and retarding the development
of an efficient adaptive immune response. The fact that we
were able to detect this unusual subpopulation in HIV-infected
patients, and a return to uninfected levels upon HAART ther-
apy, indicates that these cells arise in both lentivirus infections
and that suppression of viral replication can return their levels
to normal.
The role of monocytes in HIV infection is not fully under-
stood. Monocytes and macrophages present a variety of restric-
tion factors that can hinder viral replication, including down-
regulation of surface receptors and expression of intrinsic im-
mune proteins and microRNAs [44]. Less than 0.1% of
monocytes from patients contain HIV DNA [62], which is in
accordance with the results presented in this study. On the
other hand, replication-competent virus can be recovered
from blood monocytes, even from patients undergoing
HAART [63], which makes these cells pivotal components for
the establishment of virus latency in tissues and the develop-
ment of eradication therapies. A specific monocyte subset,
CD14CD16, has been reported to expand during AIDS in
humans and macaques [4, 8, 23, 47]. This intermediate sub-
population, phenotypically located between classical and non-
classical subsets, expresses higher levels of CCR5 and CD4 and
may be preferentially more susceptible to HIV and SIV infec-
tion than the other subgroups. We observed no significant dif-
ference in the levels of SIV DNA between intermediate and
classical monocytes, although there was a dramatic difference
between both subsets and CD14highCD16CCR2low/neg cells.
As most studies consider CD14CD16 a uniform population,
it is possible that the large number of the CCR2low/neg cells
during infection is masking the actual prevalence of SIV DNA
in authentic classical monocytes. Furthermore, CD14high
CD16CCR2low/neg monocytes also present higher levels of
CCL20, which binds to CCR6 and is able to inhibit HIV repli-
cation by inducing apolipoprotein B mRNA-editing, enzyme-
catalytic, polypeptide-like 3G in lymphocytes [64]. An auto-
crine response could explain why these cells are refractory to
SIV infection, but CCR6 surface was not detectable in ma-
caque monocytes (Fig. 3B). The dramatic difference in the
number of SIV DNA copies between classical CCR2high and
CCR2low/neg classical monocytes could corroborate the theory
that these latter cells originate from monoblasts and are origi-
nally resistant to infection because of their low levels of CD4
and CCR5 surface expression. We hypothesize that the discrep-
ancy between these subpopulations may simply reflect the vari-
able ratios by which classical monocytes differentiate into
other phenotypes [12], such as inflammatory tissue macro-
phages, DCs, intermediate monocytes, and the CCR2low/neg
subset, under inflammatory conditions. In addition, SIV- and
HIV-infected monocytes are reported to undergo phenotypic
changes, including apoptosis, modulation of MHC proteins,
and even up-regulation of surface CCR2 expression [43, 65,
66], which could also interfere with differentiation and traf-
ficking.
We have previously reported a rapid increase in several pro-
inflammatory cytokines in the brain of SIV-infected macaques
during acute infection, followed by a coordinated down-regula-
tion by 14 days p.i [32]. Accordingly, levels of cytokines in the
blood are also subjected to a similar regulation pattern in HIV
patients, where an intense but transient expression of high
levels of inflammatory molecules, called a “cytokine storm”,
can be observed in the first 10 days of infection [67]. The
surge of these suppressor monocytes in our model appears to
substantiate these observations, leading us to postulate that
phenotypic changes in classical monocytes may be part of an
anti-inflammatory reaction in response to the vigorous inflam-
matory process caused during HIV and SIV acute infection.
As AIDS is fundamentally an imbalance between immune
activation and immune suppression and as monocytes exhibit
plasticity, it is likely that CD14highCD16CCR2low/neg cells do
not represent a homogeneous subgroup but a heterogeneous
and mutable population that varies throughout the infectious
process or even presents different expression profiles depend-
ing on the viral strain involved. Nonetheless, their ability to
suppress lymphocyte proliferation, even before strong adaptive
responses are developed, emphasizes the importance of these
cells in understanding the early events of HIV and SIV infec-
tion.
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